Literature DB >> 10163627

Treatment options in acromegaly. Benefits and costs.

L M Weekes1, K K Ho, J P Seale.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 10163627     DOI： 10.2165/00019053-199610050-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  34 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

Review 2.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

3.  Transsphenoidal surgery for acromegaly--long-term results in 100 patients.

Authors:  F Grisoli; T Leclercq; P Jaquet; M Guibout; J P Winteler; J Hassoun; F Vincentelli
Journal:  Surg Neurol       Date:  1985-05

4.  The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.

Authors:  J C Reubi; A M Landolt
Journal:  J Clin Endocrinol Metab       Date:  1989-04       Impact factor: 5.958

5.  Effect of octreotide on glucose tolerance in acromegaly.

Authors:  B L Koop; A G Harris; S Ezzat
Journal:  Eur J Endocrinol       Date:  1994-06       Impact factor: 6.664

6.  Sleep apnea in acromegaly.

Authors:  R R Grunstein; K Y Ho; C E Sullivan
Journal:  Ann Intern Med       Date:  1991-10-01       Impact factor: 25.391

7.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

8.  Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide.

Authors:  J Marek; V Hána; M Krsek; V Justová; F Catus; F Thomas
Journal:  Eur J Endocrinol       Date:  1994-07       Impact factor: 6.664

9.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

Authors:  B Merola; A Cittadini; A Colao; D Ferone; S Fazio; D Sabatini; B Biondi; L Saccá; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.

Authors:  A Giustina; E Boni; G Romanelli; V Grassi; G Giustina
Journal:  Am J Cardiol       Date:  1995-05-15       Impact factor: 2.778
View more
  2 in total

Review 1.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

2.  Cost of management of invasive growth hormone-secreting macroadenoma.

Authors:  M Luque-Ramírez; C Paramo; C Varela da Costa; R V García-Mayor
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.